98 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00773 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.1 µMo/L |
| dbacp00774 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 4.3 µMo/L |
| dbacp00775 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5 µMo/L |
| dbacp00776 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 6.4 µMo/L |
| dbacp00777 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 7.5 µMo/L |
| dbacp00778 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.4 µMo/L |
| dbacp00779 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 5.2 µMo/L |
| dbacp00780 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.8 µMo/L |
| dbacp00781 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.7 µMo/L |
| dbacp00782 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 8.7 µMo/L |
| dbacp00783 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.2 µMo/L |
| dbacp00784 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 4.3 µMo/L |
| dbacp00785 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 6.4 µMo/L |
| dbacp00786 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.1 µMo/L |
| dbacp00787 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.4 µMo/L |
| dbacp00788 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2 µMo/L |
| dbacp00789 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.2 µMo/L |
| dbacp00790 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 7.2 µMo/L |
| dbacp00791 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.7 µMo/L |
| dbacp00792 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 3.5 µMo/L |
| dbacp00793 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 5.5 µMo/L |
| dbacp00794 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.7 µMo/L |
| dbacp00795 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.6 µMo/L |
| dbacp00796 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.2 µMo/L |
| dbacp00797 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.7 µMo/L |
| dbacp00798 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 6.5 µMo/L |
| dbacp00799 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.1 µMo/L |
| dbacp00800 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 5 µMo/L |
| dbacp00801 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 9.8 µMo/L |
| dbacp00802 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.9 µMo/L |
| dbacp00803 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 7.8 µMo/L |
| dbacp00804 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.3 µMo/L |
| dbacp03570 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03571 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03572 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03573 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03574 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03575 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 16.4 µMo/L |
| dbacp03576 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03577 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : > 83.6 µMo/L |
| dbacp03578 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03579 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03580 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03581 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03582 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03583 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 37.7 µMo/L |
| dbacp03584 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03585 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp03589 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 71 µMo/L |
| dbacp03590 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 59.8 µMo/L |
| dbacp03591 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 70.8 µMo/L |
| dbacp03592 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03593 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03594 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 15.6 µMo/L |
| dbacp03595 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 63.5 µMo/L |
| dbacp03596 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 64.7 µMo/L |
| dbacp03613 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 53 µMo/L |
| dbacp03614 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 58.7 µMo/L |
| dbacp03615 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 62.3 µMo/L |
| dbacp03616 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03617 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03618 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 14 µMo/L |
| dbacp03619 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 62.5 µMo/L |
| dbacp03620 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 58.6 µMo/L |
| dbacp03621 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03622 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03623 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >83.6 µMo/L |
| dbacp03624 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03625 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03626 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03627 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03628 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp05021 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 33 µMo/L |
| dbacp05022 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 17.8 µMo/L |
| dbacp05023 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.8 µMo/L |
| dbacp05024 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 11.1 µMo/L |
| dbacp05025 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 25.2 µMo/L |
| dbacp05026 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.7 µMo/L |
| dbacp05027 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 11.5 µMo/L |
| dbacp05028 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 10.4 µMo/L |
| dbacp05405 | Peptide K14D | KWKSFLKTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.52 ± 0.05 µMol/L |
| dbacp05406 | Peptide K14D/K22D | KWKSFLKTFKSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.40 ± 0.09 µMol/L |
| dbacp05407 | Peptide K1D/K3D/K7D /K10D/K14D/K22D | kWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 18.07 ± 0.48 µMol/L |
| dbacp05408 | Peptide K22D | KWKSFLKTFKSLKKTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.39 ± 0.02 µMol/L |
| dbacp05409 | Peptide K3D/K7D /K10D/K14D/K22D | KWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 20.41 ± 0.64 µMol/L |
| dbacp05410 | Peptide K7D | KWKSFLkTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.29 ± 0.03 µMol/L |
| dbacp05411 | Peptide K7D /K10D/K14D/K22D | KWKSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.79 ± 0.23 µMol/L |
| dbacp05412 | Peptide K7D /K14D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.06 ± 0.01 µMol/L |
| dbacp05413 | Peptide K7D /K14D/K22D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.45 ± 0.19 µMol/L |
| dbacp05414 | Peptide L12D | KWKSFLKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.63 ± 0.07 µMol/L |
| dbacp05415 | Peptide L12D/L20D | KWKSFLKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.14 ± 0.06 µMol/L |
| dbacp05416 | Peptide L20D | KWKSFLKTFKSLKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.33 ± 0.06 µMol/L |
| dbacp05417 | Peptide L6D | KWKSFlKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.23 ± 0.10 µMol/L |
| dbacp05418 | Peptide L6D/L12D | KWKSFlKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.01 ± 0.08 µMol/L |
| dbacp05419 | Peptide L6D/L12D/L17D/L20D | KWKSFlKTFKSlKKTVlHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9.69 ± 0.38 µMol/L |
| dbacp05420 | Peptide L6D/L12D/L17D/L20D/L21D | KWKSFlKTFKSlKKTVlHTllKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 12.88 ± 0.15 µMol/L |
| dbacp05421 | Peptide L6D/L12D/L20D | KWKSFlKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7.80 ± 0.26 µMol/L |
| dbacp05427 | Peptide P | KWKSFLKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.71 ± 0.07 µMol/L |